Stock listing
NASDAQ:VOR Vor Biopharma Inc. Stock
Home listing (NASDAQ) of Vor Biopharma Inc.
Follow Vor Biopharma Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:VOR
$19.19 USD +1.36 (+7.6%)
Close on Nov 20, 2026
- Day range
- $17.99 – $19.91 USDNov 20, 2026
- Volume
- 1.55M sharesNov 20, 2026
- Market cap
- $1.18B USDAt the close on Nov 20, 2026 · price × 61.43M shares outstanding
- 52-week range
- $6.69 – $26.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $19.18M USDMedian day 793,988 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VOR · Home | $19.19 USD | +1.36 (+7.6%) | 1,554,050 | $18.14 | $19.91 | $17.99 | $17.83 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VOR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $19.19 | +1.36 | +7.6% | $18.14 | $19.91 | $17.99 | 1,554,050 | |
| $17.83 | -0.35 | -1.9% | $17.85 | $18.53 | $17.78 | 793,988 | |
| $18.18 | -0.79 | -4.2% | $18.96 | $19.16 | $17.74 | 826,250 | |
| $18.97 | -0.45 | -2.3% | $19.01 | $20.29 | $18.86 | 763,208 | |
| $19.42 | +0.10 | +0.5% | $19.33 | $19.49 | $18.16 | 738,717 | |
| $19.32 | -0.77 | -3.8% | $19.61 | $19.88 | $18.99 | 796,406 | |
| $20.09 | +0.53 | +2.7% | $19.73 | $20.30 | $19.57 | 407,723 | |
| $19.56 | -0.42 | -2.1% | $19.75 | $20.23 | $19.26 | 405,778 | |
| $19.98 | +0.10 | +0.5% | $19.70 | $20.61 | $19.70 | 1,095,633 | |
| $19.88 | +1.22 | +6.5% | $19.11 | $20.00 | $18.63 | 550,771 | |
| $18.66 | -1.46 | -7.3% | $20.08 | $20.08 | $18.33 | 629,047 | |
| $20.12 | +0.26 | +1.3% | $20.63 | $20.70 | $19.49 | 415,417 | |
| $19.86 | +0.61 | +3.2% | $19.45 | $20.63 | $18.93 | 905,009 | |
| $19.25 | -0.43 | -2.2% | $19.71 | $20.00 | $18.84 | 624,085 | |
| $19.68 | -1.23 | -5.9% | $19.91 | $20.47 | $19.37 | 759,293 | |
| $20.91 | +0.26 | +1.3% | $20.80 | $21.59 | $20.66 | 965,843 | |
| $20.65 | +1.11 | +5.7% | $19.50 | $20.81 | $19.38 | 1,011,532 | |
| $19.54 | +1.21 | +6.6% | $18.36 | $19.56 | $18.02 | 769,881 | |
| $18.33 | +0.07 | +0.4% | $18.33 | $18.44 | $17.70 | 470,337 | |
| $18.26 | -0.68 | -3.6% | $18.67 | $18.81 | $17.95 | 721,000 | |
| $18.94 | 0.00 | 0.0% | $18.87 | $19.44 | $18.65 | 722,400 | |
| $18.94 | -0.09 | -0.5% | $19.18 | $19.79 | $18.79 | 817,600 | |
| $19.03 | +0.99 | +5.5% | $18.06 | $19.55 | $18.00 | 796,000 | |
| $18.04 | +0.01 | +0.1% | $18.37 | $18.72 | $17.73 | 724,800 | |
| $18.03 | -1.31 | -6.8% | $19.45 | $19.45 | $18.00 | 733,100 | |
| $19.34 | +0.59 | +3.1% | $18.85 | $20.25 | $18.78 | 696,600 | |
| $18.75 | -0.31 | -1.6% | $18.79 | $19.74 | $18.55 | 926,900 | |
| $19.06 | -0.74 | -3.7% | $19.50 | $19.95 | $18.98 | 949,400 | |
| $19.80 | -0.10 | -0.5% | $19.79 | $20.52 | $19.55 | 867,400 | |
| $19.90 | +0.77 | +4.0% | $18.99 | $20.27 | $18.85 | 1,102,400 | |
| $19.13 | +0.35 | +1.9% | $18.64 | $19.88 | $18.08 | 1,406,600 | |
| $18.78 | +0.47 | +2.6% | $18.09 | $18.90 | $17.86 | 563,100 | |
| $18.31 | -0.27 | -1.5% | $18.85 | $18.87 | $17.97 | 472,800 | |
| $18.58 | -0.11 | -0.6% | $18.63 | $19.18 | $18.07 | 648,500 | |
| $18.69 | +0.63 | +3.5% | $18.09 | $18.99 | $18.09 | 773,300 | |
| $18.06 | -1.02 | -5.3% | $18.97 | $19.30 | $18.00 | 876,200 | |
| $19.08 | +0.75 | +4.1% | $18.54 | $19.81 | $18.38 | 1,069,900 | |
| $18.33 | +0.02 | +0.1% | $18.63 | $18.77 | $17.52 | 1,384,000 | |
| $18.31 | -0.21 | -1.1% | $18.36 | $18.74 | $18.02 | 930,100 | |
| $18.52 | +0.08 | +0.4% | $18.62 | $18.71 | $17.95 | 792,800 | |
| $18.44 | -0.93 | -4.8% | $19.02 | $19.37 | $17.55 | 1,931,500 | |
| $19.37 | -2.63 | -12.0% | $22.00 | $22.02 | $18.89 | 2,763,500 | |
| $22.00 | +0.11 | +0.5% | $21.83 | $23.82 | $21.61 | 2,586,500 | |
| $21.89 | +0.49 | +2.3% | $21.82 | $22.16 | $21.44 | 1,864,100 | |
| $21.40 | -0.49 | -2.2% | $21.92 | $22.00 | $21.23 | 3,725,700 | |
| $21.89 | -0.06 | -0.3% | $22.53 | $23.05 | $21.80 | 1,544,200 | |
| $21.95 | -0.37 | -1.7% | $22.39 | $22.52 | $21.81 | 1,496,400 | |
| $22.32 | -0.76 | -3.3% | $23.06 | $23.06 | $22.04 | 729,800 | |
| $23.08 | +0.78 | +3.5% | $22.39 | $23.56 | $22.27 | 886,100 | |
| $22.30 | -0.04 | -0.2% | $22.83 | $23.47 | $22.20 | 800,400 | |
| $22.34 | -0.895 | -3.9% | $22.96 | $23.09 | $22.09 | 689,300 | |
| $23.24 | -1.865 | -7.4% | $24.47 | $24.60 | $23.21 | 823,200 | |
| $25.10 | +0.05 | +0.2% | $24.75 | $26.00 | $24.10 | 856,700 | |
| $25.05 | +0.81 | +3.3% | $24.17 | $25.17 | $24.00 | 421,800 | |
| $24.24 | -0.52 | -2.1% | $24.80 | $24.94 | $23.88 | 538,800 | |
| $24.76 | +2.12 | +9.4% | $22.77 | $24.88 | $22.67 | 824,900 | |
| $22.64 | +0.16 | +0.7% | $22.32 | $22.88 | $22.05 | 607,300 | |
| $22.48 | -0.17 | -0.8% | $22.50 | $22.76 | $22.28 | 847,700 | |
| $22.65 | -0.88 | -3.7% | $23.20 | $23.29 | $22.38 | 491,100 | |
| $23.53 | -0.14 | -0.6% | $23.62 | $23.99 | $23.14 | 622,100 | |
| $23.67 | -0.34 | -1.4% | $23.68 | $24.09 | $23.39 | 446,700 | |
| $24.01 | +1.30 | +5.7% | $23.02 | $24.45 | $23.02 | 1,219,900 | |
| $22.71 | -0.65 | -2.8% | $23.12 | $23.18 | $21.90 | 500,000 | |
| $23.36 | +0.295 | +1.3% | $23.58 | $23.86 | $23.07 | 618,100 | |
| $23.07 | -0.515 | -2.2% | $23.05 | $23.41 | $22.79 | 649,600 |
Splits
1 split · NASDAQ:VOR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:VOR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
Latest deck · Oct 2, 2026
American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting 2026
Conference · 13 slides
Latest news
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
Nov 12, 2026
Closed $19.32 (-3.8%) on Nov 12, 2026
Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference
Nov 10, 2026
Closed $19.56 (-2.1%) on Nov 10, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2026
Closed $18.66 (-7.3%) on Nov 5, 2026
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Oct 30, 2026
Closed $19.68 (-5.9%) on Oct 30, 2026
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Oct 22, 2026
Closed $18.26 (-3.6%) on Oct 23, 2026
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Sep 8, 2026
Closed $25.10 (+0.2%) on Sep 8, 2026
Vor Bio To Participate in Upcoming September Conferences
Sep 1, 2026
Closed $22.64 (+0.7%) on Sep 1, 2026
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 11, 2026
Closed $23.59 (+0.9%) on Aug 11, 2026
Vor Bio Appoints David Zaccardelli to Board of Directors
Jul 7, 2026
Closed $20.31 (+1.0%) on Jul 8, 2026
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
Jun 8, 2026
Closed $13.29 (+1.0%) on Jun 8, 2026
Vor Biopharma Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 107 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 13 decks · latest Oct 2, 2026
Where Vor Biopharma Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VOR · Home listing · This page | NASDAQ | United States | USD |
| BOATS:VOR | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $697.4M USD
- P/E
- 0.9×
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.25
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204 | US$1.17B | US$1.01B | n/a | 36.1× | n/a | 3.9× | −53.3% | 0.0× | n/a |
| OPKO Health, Inc. · NASDAQ:OPK | US$1.17B | US$1.26B | n/a | 2.5× | n/a | 1.0× | −29.5% | 0.4× | 0.90 |
| D&D Pharmatech Co., Ltd. · KRX:347850 | US$1.16B | US$1.13B | n/a | 549× | n/a | 11.5× | −785.5% | 0.8× | n/a |
| CStone Pharmaceuticals · HKEX:2616 | US$1.16B | US$974.9M | n/a | 24.1× | n/a | 6.0× | −162.1% | 0.3× | n/a |
| Structure Therapeutics, Inc. · NASDAQ:GPCR | US$1.15B | −US$82.92M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.38 |
| COMPASS Pathways Plc · NASDAQ:CMPS | US$1.14B | US$747.8M | n/a | n/a | n/a | 8.0× | n/a | 0.4× | 1.65 |
| Median of the others | US$1.17B | US$868.3M | 32.1× | 3.4× | −162.1% | 0.2× | 1.39 |
Forecasts
8 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 39.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.67 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jean-Paul Kress | Chief Executive Officer and Chairman |
| Sandy Mahatme | Chief Financial Officer, Chief Business Officer |
| Adi Osovsky | General Counsel |
| Carol Lincoln | Head of Human Resources |
| Dallan Murray | Chief Commercial Officer |
| Jeremy Sokolove | Chief Medical Officer |
| Navid Z. Khan | Chief Medical Affairs Officer |
Board
| Director | Role |
|---|---|
| Jean-Paul Kress | Chief Executive Officer and Chairman |
| Alexander Cumbo | Chair of the Compensation Committee |
| Daniella Beckman | Chair of the Audit Committee |
| David Zaccardelli | Director |
| Erez Kalir | Member of the Audit Committee |
| Fouad Namouni | Chair of the Nominating and Corporate Governance Committee |
| Michel Detheux | Member of the Audit Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 30, 2026 · Before open | −5.9% |
| Q2 2026 | Aug 11, 2026 · Before open | +0.9% |
| Q1 2026 | May 13, 2026 · Before open | −3.4% |
| Q4 2025 | Mar 30, 2026 | +23.2% |
| Q3 2025 | Nov 13, 2025 · After close | +2.7% |
| Q2 2025 | Aug 12, 2025 · After close | +21.7% |
| Q1 2025 | May 14, 2025 · After close | 0.0% |
| Q4 2024 | Mar 18, 2025 · Before open | −3.8% |
| Q3 2024 | Nov 7, 2024 · After close | +14.9% |
| Q2 2024 | Aug 8, 2024 · After close | −1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −5.5% |
| Q4 2023 | Mar 20, 2024 · After close | +8.9% |
| Q3 2023 | Nov 7, 2023 · After close | −6.5% |
| Q2 2023 | Aug 10, 2023 · After close | +14.4% |
| Q1 2023 | May 11, 2023 · After close | +0.7% |
| Q4 2022 | Mar 23, 2023 · After close | +15.3% |
| Q3 2022 | Nov 10, 2022 · After close | +5.0% |
| Q2 2022 | Aug 11, 2022 · After close | +8.4% |
| Q1 2022 | May 12, 2022 · After close | −4.1% |
| Q4 2021 | Mar 14, 2022 · After close | −0.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting 2026 | Conference | 13 slides | Oct 2, 2026 |
| Investor Presentation (September 2026) | Investor deck | 60 slides | September 2026 |
| 44th Annual J.P. Morgan Healthcare Conference 2026 | Conference | 19 slides | Jan 12, 2026 |
| Technical Presentation (October 2025) | Technical | 29 slides | Oct 28, 2025 |
| American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) 2025 | Conference | 14 slides | Oct 22, 2025 |
| Investor Presentation (September 2025) | Investor deck | 39 slides | Sep 2, 2025 |
| Investor Presentation (December 2024) | Investor deck | 38 slides | Dec 9, 2024 |
| Investor Presentation (September 2024) | Investor deck | 33 slides | Sep 5, 2024 |
| Investor Presentation (January 2024) | Investor deck | 36 slides | Jan 5, 2024 |
| Technical Presentation (December 2023) | Technical | 19 slides | December 2023 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (December 2022) | Technical | 35 slides | Dec 7, 2022 |
| ESGCT 2021 | Conference | 18 slides | Oct 21, 2021 |
| ASGCT 2021 | Conference | 21 slides | May 11, 2021 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of at-the-market sales Closed: US$48.4M raised | Aug 11, 2026 |
| Private placement of common stock Announced: about US$150M · US$10.81 a share Buyers: RA Capital Management; Forbion (granted the right to appoint one director to the board); Frazier Life Sciences; Caligan Partners; Logos Capital; Venrock Healthcare Capital Partners Use of proceeds: Clinical development of telitacicept, including Phase 3 trials in myasthenia gravis and primary Sjögren's disease, plus working capital and general corporate purposes | Dec 15, 2025 |
| Public offering of shares Update: US$115M · US$10 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Citigroup (co-lead), TD Cowen (co-lead) | Nov 13, 2025 |
| Private placement of prefunded warrants Announced: about US$175M · US$0.25 a share · Warrants at US$0.0001 Buyers: RA Capital Management (existing stockholder); Mingxin Capital; Forbion; Venrock Healthcare Capital Partners; Caligan Partners; NEXTBio Use of proceeds: To advance development of its clinical pipeline and for general corporate purposes | Jun 25, 2025 |
| Private placement of shares of common stock and accompanying warrants Announced: about US$55.6M · US$0.9943 a share · Warrants at US$0.838 · Stifel Dealers: Stifel (lead) Buyers: Reid Hoffman (led the PIPE as new investor; granted one board seat and one board observer seat); RA Capital Management (existing investor and largest stockholder; participated) Use of proceeds: Fund clinical and preclinical development of its pipeline candidates and general corporate purposes | Dec 27, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Feb 5, 2021.
- Price
- US$18.00 a share
- Shares offered
- 9,828,017 shares of common stock
- Offering size
- US$176.9 million
- Underwriters' option
- Up to 1,474,202 more shares
- Underwriters
- Goldman Sachs & Co. LLC, Evercore ISI, Barclays, Stifel · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 6, 2020 |
| Filed publicly | Jan 15, 2021 |
| Amended twice | Newest Feb 3, 2021 |
| Shares registered with an exchange | Feb 1, 2021 |
| Declared effective by the SEC | Feb 4, 2021 |
| Final prospectus, with the price | Feb 8, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 8, 2021 |
| S-1MEF · Registration of more shares for the same offering | Feb 5, 2021 |
| EFFECT · Notice that a registration is effective | Feb 4, 2021 |
| CERT · Exchange's certificate of listing | Feb 3, 2021 |
| FWP · Free writing prospectus | Feb 3, 2021 |
| S-1/A · Registration statement, amended | Feb 3, 2021 |
| CORRESP · Letter to the SEC | Feb 2, 2021 |
| CORRESP · Letter to the SEC | Feb 2, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 1, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
All 20 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Feb 1, 2021 |
| UPLOAD · Letter from the SEC | Jan 27, 2021 |
| CORRESP · Letter to the SEC | Jan 21, 2021 |
| CORRESP · Letter to the SEC | Jan 15, 2021 |
| S-1 · Registration statement | Jan 15, 2021 |
| UPLOAD · Letter from the SEC | Jan 4, 2021 |
| DRSLTR · Letter to the SEC with a draft | Dec 18, 2020 |
| DRS/A · Draft registration statement, amended | Dec 18, 2020 |
| UPLOAD · Letter from the SEC | Dec 4, 2020 |
| DRS · Draft registration statement | Nov 6, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 8, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Research and development | 321.5M | 93.3M | 94.3M | 64.5M | 47.5M | 31.6M |
| Operating income | -371.6M | -121.2M | -126.0M | -93.4M | -69.0M | -43.4M |
| Depreciation and amortization | 2.89M | 3.53M | 3.49M | 2.52M | 1.43M | 605.0K |
| EBITDA | -368.8M | -117.7M | -122.5M | -90.9M | -67.6M | -42.8M |
| Net income | -696.0M | -116.9M | -117.9M | -92.1M | -68.9M | -43.3M |
| Earnings per share, basic | -70.50 | -34.03 | -1.75 | -2.33 | -2.10 | -230.57 |
| Earnings per share, diluted | -70.50 | -34.03 | -1.75 | -2.33 | -2.10 | -230.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 396.5M | 81.9M | 31.4M | 57.7M | 119.8M | 48.5M |
| Short-term investments | 58.7M | 9.98M | 105.8M | 172.5M | 87.7M | 0 |
| Current assets | 458.1M | 96.5M | 140.8M | 236.9M | 214.4M | 49.1M |
| Property, plant and equipment | 533.0K | 6.58M | 10.1M | 12.6M | 6.85M | 4.73M |
| Total assets | 464.1M | 142.9M | 198.1M | 299.4M | 242.6M | 75.9M |
| Accounts payable | 5.13M | 1.50M | 815.0K | 1.77M | 1.54M | 2.36M |
| Current liabilities | 25.2M | 18.6M | 15.6M | 13.1M | 10.2M | 10.2M |
| Total liabilities | 628.4M | 46.2M | 47.4M | 48.8M | 26.3M | 27.6M |
| Shareholders' equity | -164.3M | 96.7M | 150.7M | 250.6M | 216.3M | -59.1M |
| Shares outstanding | 38.7M | 6.24M | 67.9M | 66.0M | 37.2M | 505.1K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -142.7M | -99.7M | -100.3M | -85.1M | -69.1M | -36.3M |
| Capital spending | -941.0K | -229.0K | -1.07M | -8.46M | -3.89M | -4.16M |
| Free cash flow | -143.7M | -99.9M | -101.4M | -93.6M | -73.0M | -40.5M |
| Cash from investing | -48.8M | 96.9M | 71.0M | -94.1M | -91.7M | -4.16M |
| Cash from financing | 503.8M | 53.4M | 2.94M | 117.1M | 232.9M | 82.5M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in cash | 312.3M | 50.6M | -26.3M | -62.1M | 72.1M | 42.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Oct 30, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 30, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Sep 4, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 7, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | May 7, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | May 4, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 1, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 27, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 9, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 1, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 1, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 5, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 5, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 2, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 30, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 8-K · Current report | Jan 2, 2026 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Dec 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 19, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 18, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2025 | Management or board change | SEC |
| 424B3 · Prospectus | Dec 1, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 10, 2025 | Offer document | SEC |
| S-3/A · Registration statement, amended | Nov 10, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 3, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 27, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 20, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 20, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Sep 30, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 25, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Sep 24, 2025 | Offer document | SEC |
| S-3 · Registration statement | Sep 24, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 9, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 27, 2025 | Management or board change | SEC |
| 8-K · Current report | Aug 27, 2025 | Management or board change | SEC |
| 424B5 · Prospectus | Aug 27, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Aug 11, 2025 | Other filings | SEC |
| DEF 14A · Proxy statement | Aug 8, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Jul 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 22, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 10, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jul 10, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 9, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 27, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 20, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2025 | Management or board change | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| DEFR14A | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 8, 2025 | Annual report | SEC |
This page holds 200 of 466 filings. Open Filings
Cap table
Built by 6ix from Vor Biopharma Inc.’s releases · as of Oct 26, 2026
- Common shares
- 61,434,344
- Fully diluted
- 61,434,344
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 61,434,344 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 61,434,344 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Feb 4, 2021 |
| Alexander Cumbo Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Climb Bio, Inc. (Director · Since at least Mar 28, 2025); Solid Biosciences Inc. (President and CEO, Director · Since at least Dec 2, 2022); Verve Therapeutics Inc (Director · Since at least Jun 9, 2022); Ra Pharmaceuticals Inc (Director · Nov 14, 2018 – Apr 2, 2020 · Past); Sarepta Therapeutics, Inc. (EVP, Chief Commercial Officer · Mar 5, 2018 – Feb 28, 2020 · Past) | Chair of the Compensation Committee · Since at least Jul 16, 2025 |
| Daniella Beckman Other companies: Upstream Bio, Inc. (Member, Board of Directors · Since at least Oct 10, 2024); Blueprint Medicines Corp (Director · Since at least Dec 8, 2021); Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 10, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Translate Bio Inc (Director · Jun 18, 2019 – Sep 14, 2021 · Past) | Chair of the Audit Committee · Since at least Feb 4, 2021 |
| Joshua Resnick Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Cidara Therapeutics Inc (Director · Since at least Jan 3, 2025); PepGen Inc. (Director · Since at least Jun 20, 2024); Jade Biosciences, Inc. (Director · Jun 5, 2024 – Jun 5, 2024 · Past) | Director · May 23, 2024 – May 22, 2025 · Past |
| Matthew R Patterson Other companies: 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 14, 2023 · Past); Audentes Therapeutics Inc (Chief Executive Officer, Director · Jul 19, 2016 – Jan 15, 2020 · Past) | Director · Feb 4, 2021 – May 22, 2025 · Past |
| David Zaccardelli Other companies: SAB Biotherapeutics, Inc. (Chair of the Board · Since at least Jan 5, 2026); Verona Pharma plc (President and CEO, Director · Since at least Aug 7, 2024) | Director · Since at least Jul 7, 2026 |
| Jean-Paul Kress Other companies: Biogen Inc. (EVP Pres Int'l & Global Hd GTO · Jun 14, 2017 – Jul 3, 2017 · Past); Sarepta Therapeutics, Inc. (Director · Mar 10, 2017 – Mar 10, 2017 · Past) | Chief Executive Officer and Chairman · Since at least Jun 25, 2025 |
| Peter Kolchinsky Other companies: Artiva Biotherapeutics, Inc. (Director · Since at least Jun 12, 2026); ARS Pharmaceuticals, Inc. (Director · Since at least Sep 30, 2025) | Director · Since at least Apr 2, 2026 |
| Wouter Joustra Other companies: enGene Therapeutics Inc. (Director · Since at least May 15, 2024); NewAmsterdam Pharma Company N.V. (Director · Jul 16, 2024 – Jul 16, 2024 · Past) | Director · Since at least Dec 18, 2025 |
| Amy Quinlan Other companies: Voyager Therapeutics, Inc. (Principal Accounting Officer · Since at least May 8, 2026) | Vice President of Finance · Jun 21, 2024 – Nov 6, 2024 · Past |
All 29 people
| Person | Seat |
|---|---|
| Andrew David Levin Other companies: Climb Bio, Inc. (Director · Since at least Aug 9, 2021) | Director · Since at least Dec 18, 2025 |
| Dallan Murray Other companies: Sarepta Therapeutics, Inc. (Chief Customer Officer · Apr 24, 2024 – Mar 7, 2025 · Past) | Chief Commercial Officer · Since at least Aug 4, 2025 |
| Eyal C Attar Other companies: Aprea Therapeutics, Inc. (SVP, Chief Medical Officer, Director · Oct 2, 2019 – Jun 3, 2022 · Past) | CHIEF MEDICAL OFFICER · Oct 11, 2022 – Feb 13, 2025 · Past |
| Michel Detheux Other companies: Iteos Therapeutics Inc (Chief Executive Officer, Director · Since at least Jul 23, 2020) | Member of the Audit Committee · Since at least Jul 16, 2025 |
| Nathan D Jorgensen Other companies: Voyager Therapeutics, Inc. (Chief Financial Officer · Since at least Jul 8, 2024) | CHIEF FINANCIAL OFFICER · Feb 4, 2021 – May 6, 2024 · Past |
| Adi Osovsky | General Counsel · Since at least Sep 2, 2025 |
| Carol Lincoln | Head of Human Resources · Since at least Nov 5, 2026 |
| Christopher Slapak | Chief Medical Officer · Feb 4, 2021 – Feb 1, 2022 · Past |
| Erez Kalir | Member of the Audit Committee · Since at least Jan 8, 2025 |
| Fouad Namouni | Chair of the Nominating and Corporate Governance Committee · Since at least Nov 5, 2026 |
| Han Wook Choi | Chief Financial Officer · Sep 30, 2024 – May 1, 2025 · Past |
| Jeremy Sokolove | Chief Medical Officer · Since at least Nov 3, 2025 |
| Navid Z. Khan | Chief Medical Affairs Officer · Since at least Sep 23, 2025 |
| Qing Zuraw | Chief Development Officer · Since at least Jul 17, 2025 |
| Robert Ang | PRESIDENT AND CEO, Director · Nov 6, 2023 – May 6, 2025 · Past |
| Sadik Kassim | Chief Technology Officer · Feb 4, 2021 – Feb 4, 2021 · Past |
| Sandy Mahatme | Chief Financial Officer, Chief Business Officer · Since at least Jul 10, 2025 |
| Sarah Burgess Reed | Director · Since at least Aug 27, 2025 |
| Tirtha Chakraborty | Chief Sci Off & Head Tech Ops · Feb 4, 2021 – May 6, 2025 · Past |
Log in to ask 6ix AI your own questions about Vor Biopharma Inc.